<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416962</url>
  </required_header>
  <id_info>
    <org_study_id>CSYO380A2101</org_study_id>
    <nct_id>NCT00416962</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine</brief_title>
  <official_title>An Open-Label, Multiple Dose, Randomized, Three-Period Crossover Study in Healthy Volunteers to Evaluate the Effect of co-Administration of Amantadine 100 mg BID and Oseltamivir 75 mg BID on the Pharmacokinetic Properties of Amantadine and Oseltamivir.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is designed to assess the safety and pharmacokinetic effects of oseltamivir&#xD;
      administration alone or in combination with amantadine in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the pharmacokinetics of amantadine following twice daily administration alone or in combination with twice daily oseltamivir in healthy volunteers.</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the pharmacokinetics of oseltamivir following twice daily administration alone or in combination with twice daily amantadine in healthy volunteers.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of twice daily oseltamivir and twice daily amantadine when given alone and when given in combination.</measure>
  </secondary_outcome>
  <enrollment>18</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amantadine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oseltamivir phosphate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subjects aged 18 to 45 years, and in good health as determined&#xD;
             by past medical history, physical examination, vital signs, electrocardiogram, and&#xD;
             laboratory tests&#xD;
&#xD;
          -  Vital signs within the following ranges:&#xD;
&#xD;
               -  oral body temperature 35.0 - 37.5°C&#xD;
&#xD;
               -  systolic blood pressure 90 - 140 mm Hg&#xD;
&#xD;
               -  diastolic blood pressure 50 - 90 mm Hg&#xD;
&#xD;
               -  pulse rate 40 - 90 bpm&#xD;
&#xD;
          -  Female subjects of child bearing potential must be using double-barrier local&#xD;
             contraception (for example, intra-uterine device plus condom, or spermicidal gel plus&#xD;
             condom) or have been surgically sterilized at least 6 months prior before study start,&#xD;
             with supportive clinical documentation OR Postmenopausal women must have no regular&#xD;
             menstrual bleeding for at least 1 year prior to inclusion.&#xD;
&#xD;
          -  Body mass index must be within 18 - 30 kg/m2. Subjects must weigh at least 50 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers (use of tobacco products in the previous 3 months). Smokers will be defined as&#xD;
             those who report tobacco use or have a urine cotinine greater than 500 ng/mL&#xD;
&#xD;
          -  Female subjects who are pregnant or lactating&#xD;
&#xD;
          -  Participation in any clinical investigation involving medical intervention within 4&#xD;
             week prior to study start.&#xD;
&#xD;
          -  Donation or loss of ≥ 400 mL of blood within 8 weeks prior to study start, or longer&#xD;
             if required by local regulation.&#xD;
&#xD;
          -  Significant illness within 2 weeks before study start.&#xD;
&#xD;
          -  A past personal or close family medical history of clinically significant ECG&#xD;
             abnormalities or of a prolonged QT-interval syndrome.&#xD;
&#xD;
          -  History of autonomic dysfunction (for example, history of fainting).&#xD;
&#xD;
          -  History of acute or chronic bronchospastic disease (including asthma and chronic&#xD;
             obstructive pulmonary disease, treated or untreated),&#xD;
&#xD;
          -  History of clinically significant drug allergy or history of atopic allergy (asthma,&#xD;
             urticaria, eczematous dermatitis). A known hypersensitivity to the study drug or to&#xD;
             similar drugs.&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism or excretion of drugs, or which may jeopardize the subject in&#xD;
             case of participation in the study, including bowel, gastrointestinal, renal,&#xD;
             pancreatic, hepatic, hematological, immunological, or neurological disorders.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936-1080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>November 29, 2007</last_update_submitted>
  <last_update_submitted_qc>November 29, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2007</last_update_posted>
  <keyword>Oseltamivir, amantidine, Symmetrel, Tamiflu</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

